NEWS

Livestream Review | Taimei Technology's Cai Xin: AI Clinical Development Reshapes the Industry Value Chain

AI Translation


On September 15, at the trading roundtable of the "China Innovative Medical Assets Lounge" co-hosted by Arterial Network and Weijieyao, Cai Xin, Global Head of Clinical Research Delivery at Taimei Technology, together with securities industry representatives and CRO company executives, analyzed the opportunities and challenges facing the CXO industry under the AI wave.

Cai Xin stated during the livestream: The AI pharmaceutical boom has significantly accelerated the discovery of candidate molecules. Accelerating the value validation of candidate molecules in clinical development through AI will become the key in the next phase. Moreover, judging from orders, AI-driven clinical development has moved beyond the proof-of-concept stage and entered large-scale industrial implementation. In the future, CXOs that combine "AI platform empowerment + professional delivery capabilities" will hold an advantage in competition.

 

What is the commercial value of AI clinical development? A set of data explains

AI brings not only improved execution efficiency and changes in work modes, but also a redistribution of industry value. During the livestream, the guests discussed the actual results of AI commercialization, its value to CXOs, and future development directions.

On the topic of "the commercial value of AI clinical development platforms," Cai Xin cited a set of data:

 On August 26, Zhejiang Taimei Medical Technology Co., Ltd. announced its interim performance report for the period ended June 30, 2026. In the first half of 2026, the company's newly added contract amount reached RMB 364 million, a year-on-year increase of 15%, of which new contracts from the AI clinical development platform reached RMB 266 million, a substantial year-on-year increase of 47%.

The commercialization process of Wiz.AI, the core of the AI clinical development platform, has accelerated. During the reporting period, the newly added contract amount was RMB 124 million, a year-on-year increase of 67%, and revenue also increased by 48% year-on-year. The AI agent product matrix continues to gain recognition from industry clients.

"Overall, the company's AI clinical development platform business has grown strongly, gross margin has continued to improve, and the commercial value of AI technology is being realized at an accelerating pace," said Cai Xin.

How does AI clinical development reshape industry value? Evidence from multiple implementation cases

How AI clinical development drives the reconstruction of industry value was the core topic of this livestream. During the livestream, the guests shared their views on the key links of AI implementation, actual results, and commercial value.

Cai Xin stated that "AI for Success" is the core concept of Taimei Technology's AI technology development. It also has a clear classification of the positioning, value, and implementation paths of the AI Agent matrix, such as AI For Productivity (efficiency improvement), AI For Information (information integration), and AI For Science (scientific research), using different AI capabilities to cover the full scenarios of clinical research, including clinical protocol optimization and prediction, clinical operations, data management and statistics, medical monitoring, endpoint assessment, pharmacovigilance, and all other key links.

Taking AI For Productivity (efficiency improvement) as an example, the iDM data management agent can increase database building efficiency by 80%, the iCTA document management agent reduces attribute filling time by 70%, and the iPV pharmacovigilance agent reduces the cost of processing 1,000 reports to only one-third of the traditional manual mode. In these high-frequency repetitive areas with good digital foundations, fixed processes, and unified acceptance standards, AI clinical development has achieved very significant results.

For CXOs and innovative pharmaceutical companies, AI clinical development is not only about efficiency improvement and cycle shortening, but also a transformation of the development paradigm and organizational form. In the future, CXO businesses that simply compete on manpower, scale, and price will continue to face pressure, but CXOs with AI clinical development platforms and clinical professional capabilities, and that deeply integrate AI capabilities with delivery capabilities, will have significant advantages.

Taking Taimei Technology as an example,

In South Korea, Taimei Technology signed an enterprise-level strategic cooperation agreement with C&R Research, a leading Korean CRO company, to fully export clinical development digital intelligent solutions and AI Agent intelligent modules;

In Australia, Taimei Technology's collaboration project with GreenLight Clinical (GLC), a well-known Australian CRO company, has been successfully delivered and recognized by the partner.

"Human in the loop" principle

Finally, Cai Xin emphasized that the implementation and application of AI clinical development must adhere to the "human in the loop" principle. From the very beginning of product design, there must be a clear understanding of application scenarios, risk management, and the delineation of decision-maker responsibilities. Adhere to the "AI for Success" concept, ensure delivery effectiveness, and avoid AI for AI's sake.